ReviewInternational journal of molecular sciences2023
Flavonols in Action: Targeting Oxidative Stress and Neuroinflammation in Major Depressive Disorder.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 41 citations in OpenAlex.
- Systematic Literature Review of Functional Snacks: Bioactive Properties, Food Technologies, and Consumer Acceptance.Foods (Basel, Switzerland) · 2026Review
- Ethnobotanical Uses and Phytochemical, Pharmacological, Behavioral, and Toxicological Effects ofMolecules (Basel, Switzerland) · 2026Review
- Development and characterization of a reserpine-induced mouse model of depression: An integrated in-vivo and in-silico approach.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Effect of Gouteng Jiangya Jieyu Prescription on Neuronal Damage in Rats With Hypertension Complicated by Depression via ROS/AKT/NF-κB Pathway.Pulmonary circulation · 2026Article
- Flavonoids as Modulators of Neuroinflammation in Affective Disorders: A Narrative Review.International journal of molecular sciences · 2026Review
- Auranofin reimagined: an emerging therapeutic candidate for neurodegenerative diseases through molecular mechanistic insights.Inflammopharmacology · 2026Review
- Schaftoside inhibits neuroinflammation and exerts antidepressant effects through METTL3-mediated m6A modification of circ_0001470 sponging miR-183-5p to regulate MAP3K1 expression.Psychopharmacology · 2026Article
- Curcumin reprograms metabolic pathways and MAPK signaling to exert antidepressant effects.Biochemistry and biophysics reports · 2026Article
- Antidepressant and Cognitive-Enhancing Effects ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Article
- Comparative Study on Extracts from Traditional Medicinal PlantsPharmaceuticals (Basel, Switzerland) · 2025Article
- 5-Hydroxymethylfurfural Alleviates Lipopolysaccharide-Induced Depression-like Behaviors by Suppressing Hypothalamic Oxidative Stress and Regulating Neuroinflammation in Mice.Antioxidants (Basel, Switzerland) · 2025Article
- Brain Structures, Circuits, and Networks Involved in Immune Regulation, Periodontal Health, and Disease.Life (Basel, Switzerland) · 2025Review
- Review
- Neurobiological Mechanisms of Electroconvulsive Therapy: Molecular Perspectives of Brain Stimulation.International journal of molecular sciences · 2025Review
- Coenzyme Q10 protects keratinocytes against oxidation-induced energy stress as revealed by spatiotemporal analysis of cell energetics.Scientific reports · 2025Article
- Schaftoside Reduces Depression- and Anxiogenic-like Behaviors in Mice Depression Models.Brain sciences · 2025Article
- Antidepressant and neuromodulatory potential of hydroalcoholic extract ofTranslational neuroscience · 2025Article
- Trends in research on novel antidepressant treatments.Frontiers in pharmacology · 2025Review
- Pro-Inflammatory Biomarkers And Depression: A Study Performed In A Group Of Health Sciences University Students.Neuropsychiatric disease and treatment · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder is one of the most common mental illnesses that highly impairs quality of life. Pharmacological interventions are mainly focused on altered monoamine neurotransmission, which is considered the primary event underlying the disease's etiology. However, many other neuropathological mechanisms that contribute to the disease's progression and clinical symptoms have been identified. These include oxidative stress, neuroinflammation, hippocampal atrophy, reduced synaptic plasticity and neurogenesis, the depletion of neurotrophic factors, and the dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis. Current therapeutic options are often unsatisfactory and associated with adverse effects. This review highlights the most relevant findings concerning the role of flavonols, a ubiquitous class of flavonoids in the human diet, as potential antidepressant agents. In general, flavonols are considered to be both an effective and safe therapeutic option in the management of depression, which is largely based on their prominent antioxidative and anti-inflammatory effects. Moreover, preclinical studies have provided evidence that they are capable of restoring the neuroendocrine control of the HPA axis, promoting neurogenesis, and alleviating depressive-like behavior. Although these findings are promising, they are still far from being implemented in clinical practice. Hence, further studies are needed to more comprehensively evaluate the potential of flavonols with respect to the improvement of clinical signs of depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.